Table 1.

miR-655-3p expression and clinicopathological features in hepatocellular carcinoma patients

Characteristics	miR-655-3p expression			p-value
	Cases	Low	middle/High
Age (years)
≥ 53	43	27(62.8 %)	16(37.2 %)	0.69
< 53	41	24(58.5 %)	17(41.5 %)
Gender
Male	71	45(63.4 %)	26(36.6 %)	0.242
Female	13	6(46.2 %)	7(53.8 %)
HBsAg status
Positive	62	36(58.1 %)	26(41.9 %)	0.404
Negative	22	15(68.2 %)	7(31.8 %)
AFP (ng/ml)
≥ 20	48	30(62.5 %)	18(37.5 %)	0.699
< 20	36	21(58.3 %)	15(41.7 %)
Liver cirrhosis
Yes	63	38(60.3 %)	25(49.7 %)	0.897
No	21	13(61.9 %)	8(39.1 %)
Tumour size (cm)
< 5	44	22(50 %)	22(50 %)	0.035*
≥ 5	40	29(72.5 %)	11(27.5 %)
PVTT
Yes	9	9(100.0 %)	0(0.0 %)	0.028*
No	75	42(56 %)	33(44 %)
TNM Classification
I + II	50	24(48 %)	26(52 %)	0.004**
III + IV	34	27(79.4 %)	7(20.6 %)
Tumour differentiation
Well	37	21(56.8 %)	16(43.2 %)	0.721
Moderate	34	21(61.8 %)	13(48.2 %)
Poor	13	9(69.2 %)	4(30.8 %)
Metastasis
Yes	33	27(81.8 %)	6(18.2 %)	0.001**
No	51	24(47.1 %)	27(52.9 %)

Abbreviations: AFP alpha-fetoprotein, HBsAg hepatitis B surface antigen, TNM tumor-node-metastasis, PVTT portal vein tumor thrombosis. * p<0.05; ** p<0.01